The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer

Abstract CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anthony Goncalves, Pascal Finetti, Daniel Birnbaum, François Bertucci
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ecafbdc5cfd6482fbd26fa13182d387e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ecafbdc5cfd6482fbd26fa13182d387e
record_format	dspace
spelling	oai:doaj.org-article:ecafbdc5cfd6482fbd26fa13182d387e2021-12-02T14:41:54ZThe CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer10.1038/s41523-021-00256-22374-4677https://doaj.org/article/ecafbdc5cfd6482fbd26fa13182d387e2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00256-2https://doaj.org/toc/2374-4677Abstract CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independent prognostic value in the Luminal B subtype and not in the other subtypes. In Luminal B patients receiving adjuvant endocrine therapy but no chemotherapy, CINSARC identified patients with different 5-year DFS (90% [95%CI 86–95] in low-risk vs. 79% [95%CI 75–84] in high-risk, p = 1.04E−02). Luminal B CINSARC high-risk tumors were predicted to be less sensitive to endocrine therapy and CDK4/6 inhibitors, but more vulnerable to homologous recombination targeting and immunotherapy. We concluded that CINSARC adds prognostic information to that of clinicopathological features in Luminal B breast cancers, which might improve patients’ stratification and better orient adjuvant treatment. Moreover, it identifies potential therapeutic avenues in this aggressive molecular subtype.Anthony GoncalvesPascal FinettiDaniel BirnbaumFrançois BertucciNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Anthony Goncalves Pascal Finetti Daniel Birnbaum François Bertucci The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
description	Abstract CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independent prognostic value in the Luminal B subtype and not in the other subtypes. In Luminal B patients receiving adjuvant endocrine therapy but no chemotherapy, CINSARC identified patients with different 5-year DFS (90% [95%CI 86–95] in low-risk vs. 79% [95%CI 75–84] in high-risk, p = 1.04E−02). Luminal B CINSARC high-risk tumors were predicted to be less sensitive to endocrine therapy and CDK4/6 inhibitors, but more vulnerable to homologous recombination targeting and immunotherapy. We concluded that CINSARC adds prognostic information to that of clinicopathological features in Luminal B breast cancers, which might improve patients’ stratification and better orient adjuvant treatment. Moreover, it identifies potential therapeutic avenues in this aggressive molecular subtype.
format	article
author	Anthony Goncalves Pascal Finetti Daniel Birnbaum François Bertucci
author_facet	Anthony Goncalves Pascal Finetti Daniel Birnbaum François Bertucci
author_sort	Anthony Goncalves
title	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
title_short	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
title_full	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
title_fullStr	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
title_full_unstemmed	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
title_sort	cinsarc signature predicts the clinical outcome in patients with luminal b breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ecafbdc5cfd6482fbd26fa13182d387e
work_keys_str_mv	AT anthonygoncalves thecinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT pascalfinetti thecinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT danielbirnbaum thecinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT francoisbertucci thecinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT anthonygoncalves cinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT pascalfinetti cinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT danielbirnbaum cinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer AT francoisbertucci cinsarcsignaturepredictstheclinicaloutcomeinpatientswithluminalbbreastcancer
_version_	1718389905449549824

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer

Ejemplares similares